Loading

Please wait...

Copiktra

Generic Name: duvelisib (DOO ve LIS ib)
Brand Names: Copiktra
Copiktra (duvelisib) is used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma. Includes Copiktra side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Copiktra

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Copiktra (duvelisib) is a prescription medicine used to treat adults with chronic lymphocytic leukemia or small lymphocytic leukemia. Copiktra is also used to treat follicular lymphoma. Copiktra is given after at least two other cancer treatments did not work or have stopped working. It is not known if Copiktra is safe and effective in children less than 18 years of age. Copiktra can cause serious or fatal side effects, including serious infections, severe diarrhea, or a life-threatening skin rash. Learn more

Copiktra Side Effects

Copiktra Side Effects

Note: This document contains side effect information about duvelisib. Some of the dosage forms listed on this page may not apply to the brand name Copiktra.

For the Consumer

Applies to duvelisib: oral capsule

Warning

Oral route (Capsule)

Warning: Fatal and Serious Toxicities: Infections, Diarrhea, or Colitis, Cutaneous Reactions, and PneumonitisFatal and/or serious infections occurred in 31% of duvelisib-treated patients. Monitor for signs and symptoms of infection. Withhold duvelisib if infection is suspected. Fatal and/or serious diarrhea or colitis occurred in 18% of duvelisib-treated patients. Monitor for the development of severe diarrhea or colitis. Withhold duvelisib. Fatal and/or serious cutaneous reactions occurred in 5% of duvelisib-treated patients. Withhold duvelisib. Fatal and/or serious pneumonitis occurred in 5% of duvelisib-treated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Withhold duvelisib.

Along with its needed effects, duvelisib (the active ingredient contained in Copiktra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking duvelisib:

More common

  • Black, tarry stools
  • bleeding gums
  • blistering, peeling, or loosening of the skin
  • blood in the urine or stools
  • body aches or pain
  • chest pain
  • chills
  • cough
  • cracked lips
  • decreased urine
  • difficulty in swallowing
  • dry mouth
  • ear congestion
  • fever
  • headache
  • increased thirst
  • irregular heartbeat
  • itching
  • joint or muscle pain
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • mood changes
  • muscle pain or cramps
  • nasal congestion
  • nausea
  • numbness or tingling in the hands, feet, or lips
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • runny nose
  • seizures
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stomach cramps or pain
  • swelling
  • tenderness
  • tightness in the chest
  • troubled breathing
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • watery or bloody diarrhea

Some side effects of duvelisib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bone pain
  • constipation
  • decreased appetite
  • difficulty in moving
  • muscle stiffness
  • vomiting

For Healthcare Professionals

Applies to duvelisib: oral capsule

Hematologic

Very common (10% or more): Neutropenia (63%), thrombocytopenia (39%), anemia (45%), lymphocytosis (30%), leukopenia (29%), lymphopenia (21%)

Immunologic

Very common (10% or more): Infection/sepsis (31%)

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (20%), arthralgia (10%)

Metabolic

Very common (10% or more): Lipase increased (36%), hypophosphatemia (31%), ALP increased (29%), serum amylase increased (28), hyponatremia (27%), hyperkalemia (J26%), hypoalbuminemia (25%), creatinine increased (24%), hypocalcemia (23%), decreased appetite (14%), edema (14%), hypokalemia (10%)

Hepatic

aminotransferase increased, aspartate aminotransferase increased, transaminases increased, hypertransaminasemia, hepatocellular injury, hepatotoxicity) (15%)

Respiratory

Very common (10% or more): Cough (25%), dyspnea (12%)

Common (1% to 10%): Pneumocystis jirovecii pneumonia (PJP), cytomegalovirus (CMV) reactivation/infection

Other

Very common (10% or more): Fatigue (29%), pyrexia (26%)

General

The most common adverse reactions (reported in 20% or more of patients) were diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, and anemia.

Nervous system

Very common (10% or more): Headache (12%)

Renal

Very common (10% or more): Upper respiratory tract infection (21%), pneumonia (21%), lower respiratory tract infection (10%)

Dermatologic

Very common (10% or more): Rash (e.g., dermatitis [including allergic, exfoliative, perivascular], erythema [including multiforme], rash [including exfoliative, erythematous, follicular, generalized, macular/papular, pruritic, pustular], toxic epidermal necrolysis, toxic skin eruption, drug reaction with eosinophilia and systemic symptoms, drug eruption, Stevens-Johnson syndrome)

Common (1% to 10%): Cutaneous reactions

Frequency not reported: Drug reaction with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN)

Gastrointestinal

Very common (10% or more): Diarrhea/colitis (includes colitis, enterocolitis, colitis microscopic, colitis ulcerative, diarrhea, diarrhea hemorrhagic) (50%), nausea (24%), abdominal pain (18%), vomiting (16%), mucositis (14%), constipation (13%)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Copiktra